ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 09/26/2014

ClinicalTrials.gov ID: NCT01145560

Study Identification

Unique Protocol ID:	D0620C00003
Brief Title:	A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock
Official Title:	A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock
Secondary IDs:	

Study Status

Record Verification:	September 2014
Overall Status:	Completed
Study Start:	October 2010
Primary Completion:	May 2012 [Actual]
Study Completion:	May 2012 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	Yes

Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No
IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: 5534 Serial Number: 111 Has Expanded Access? No
Review Board:	Approval Status: Board Name: Board Affiliation: Phone: Email:
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	United States: Food and Drug Administration Australia: Department of Health and Ageing Therapeutic Goods Administration Belgium: Federal Agency for Medicinal Products and Health Products Canada: Canadian Institutes of Health Research France: Ministry of Health Germany: Federal Institute for Drugs and Medical Devices Spain: Ministry of Health

Study Description

Brief Summary:	The primary purpose of this study to evaluate the effect of two different doses of AZD9773 (CytoFab™) versus placebo on ventilator free days (VFDs) over the first 28 days after the start of dosing with AZD9773 in patients with severe sepsis and/or septic shock, who are already receiving appropriate standard of care treatment for sepsis.
Detailed Description:	

Conditions

Conditions:	Severe Sepsis Septic Shock
Keywords:	severe sepsis TNF neutralisation septic shock patients

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	3
Masking:	Double Blind (Subject, Caregiver, Investigator)
Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	300 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: 1 AZD9773 250/50 units/kg	Drug: AZD9773 A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days Other Names: • CytoFab™
Experimental: 2 AZD9773 500/100 units/kg	Drug: AZD9773 A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days Other Names: • CytoFab™
Placebo Comparator: 3	Drug: Placebo Placebo

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years

Maximum Age:

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Adults with a first episode of sepsis during this hospitalisation and objective evidence of infection that requires parenteral antibiotics.
- At least 2 of 4 SIRS criteria in the 24 hours before organ dysfunction (must include either fever OR elevated white blood cells [WBC])
- Cardiovascular or respiratory dysfunction.

Exclusion Criteria:

- Immunocompromising comorbidities or concomitant medications:
    1. Advanced human immunodeficiency virus (HIV) infection (CD4 ≤50/mm3).
    2. Stage III or IV cancer.
    3. Haemopoietic or lymphoreticular malignancies not in remission.
    4. Receiving radiation therapy or chemotherapy.
    5. Stem cell, organ or bone marrow transplant in the past 6 months.
    6. Absolute neutrophil count <500 per μL.
    7. High dose steroids or other immunocompromising drugs.
- Concomitant diseases:
    1. Deep seated fungal infection or active tuberculosis.
    2. Cirrhosis with portal hypertension or Childs-Pugh Class C.
    3. History of chronic hypercarbia, respiratory failure in past 6 months or use of home oxygen in the setting of severe chronic respiratory disease.
    4. Neuromuscular disorders that impact breathing/spontaneous ventilation.
    5. Quadriplegia.
    6. Cardiac arrest in the past 30 days.
    7. New York Heart Association functional Class IV due to heart failure or any disorder.
    8. Burns over > 30% of body surface area.
- Medication and allergy disqualifications.
    1. Treatment with anti-TNF agents within the last 8 weeks.
    2. Previously received ovine derived products (CroFab™, DigiFab™).
    3. Sheep product allergy or allergy to latex, papain, chymopapain.

Contacts/Locations

Study Officials: Gordon Bernard, MD
Study Principal Investigator
Vanderbilt University

Warren Botnick, MD
Study Director
PAREXEL International

Justin Lindemann, MD
Study Director
AstraZeneca

Wayne Dankner, MD
Study Director
PAREXEL International

Jiri Juchelka, MD
Study Director
PAREXEL International

Locations: Australia, South Australia
Research Site
Adelaide, South Australia, Australia

Australia, New South Wales
Research Site
Blacktown, New South Wales, Australia

Australia, Victoria
Research Site
Clayton, Victoria, Australia

Research Site
Footscray, Victoria, Australia

Australia, Western Australia
Research Site
Fremantle, Western Australia, Australia

Australia, Queensland
Research Site
Herston, Queensland, Australia

Research Site
Nambour, Queensland, Australia

Australia, New South Wales
Research Site
Wollongong, New South Wales, Australia

Australia, Queensland
Research Site
Woollongabba, Queensland, Australia

Belgium
Research Site
Antwerpen, Belgium, Belgium

Research Site
Brussels, Belgium, Belgium

Research Site
Genk, Belgium, Belgium

Research Site
Godinne, Belgium, Belgium

Research Site
Liege, Belgium, Belgium

Research Site
Ottignies, Belgium, Belgium

Canada, Alberta
Research Site
Edmonton, Alberta, Canada

Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada

Canada, Ontario
Research Site
Ottawa, Ontario, Canada

Canada, Quebec
Research Site
Quebec, Quebec, Canada

Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada

Research Site
Victoria, British Columbia, Canada

Canada, Ontario
Research Site
Windsor, Ontario, Canada

Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada

Research Site
Winnipeg, Manitoba, Canada

Czech Republic
Research Site
Hradec Kralove, Czech Republic

Research Site
Praha, Czech Republic

Research Site
Usti Nad Labem, Czech Republic

Finland
Research Site
Kuopio, Finland

Research Site
Tampere, Finland

France
Research Site
Angers, France

Research Site
Dijon, France

Research Site
La Roche Sur Yon, France

Research Site
Limoges, France

Research Site
Montauban, France

Research Site
Nantes, France

Research Site
Nimes, France

Research Site
Orleans, France

Research Site
Paris, France

Research Site
Poitiers, France

Research Site
Saint-michel, France

Research Site
Toulon, France

Research Site
Toulouse, France

Research Site
Tours, France

Research Site
Vandoeuvre Les Nancy, France

Spain
Research Site
Barcelona, Cataluna, Spain

Research Site
Getafe, Madrid, Spain

Research Site
Madrid, Madrid, Spain

Research Site
Oviedo, Asturias, Spain

Research Site
Palma de Mallorca, Islas Baleares, Spain

Research Site
Sabadell, Barcelona, Spain

Research Site
Santiago de Compostela, Coruna, Spain

Research Site
Terrassa, Cataluna, Spain

Research Site
Valencia, Comunidad Valenciana, Spain

References

Citations:

Links: URL: http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1665&fi...
Description CSR-D0620C00003.pdf

URL: http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1665&fi...
Description redacted-CSP-D0620C00003.pdf

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	Subjects were screened and enrolled from approximately 100 centres worldwide.

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Overall Study

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Started	100	100	100
Received Treatment	99	98	99

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Completed Treatment	69 [1]	85 [2]	78 [3]
Completed	96 [4]	96 [5]	98 [6]
Not Completed	4	4	2
Withdrawal by Subject	2	1	0
Lost to Follow-up	1	1	1
No study drug by 24h after organ failure	1	0	0
Accidental unblinding of study treatment	0	1	0
False insurance information	0	1	0
Withdrawal of therapy	0	0	1

[1] 9 patients died during the treatment period without completing the full course of treatment.
[2] 8 patients died during the treatment period without completing the full course of treatment.
[3] 7 patients died during the treatment period without completing the full course of treatment.
[4] 20 patients died during the study. Death was not a reason for treatment or study discontinuation.
[5] 33 patients died during the study. Death was not a reason for treatment or study discontinuation.
[6] 27 patients died during the study. Death was not a reason for treatment or study discontinuation.

Baseline Characteristics

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Baseline Measures

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo	Total
Number of Participants	100	100	100	300
Age, Continuous [units: years] Mean (Standard Deviation)	64.4 (15.76)	66.6 (14.61)	64.1 (15.25)	65.0 (15.21)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo	Total
Gender, Male/Female [units: Participants]				
Female	40	40	32	112
Male	60	60	68	188

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Ventilator-free Days (VFDs) Over 28 Days
Measure Description	Number of ventilator-free days (VFDs)
Time Frame	Over 28 days following first dose
Safety Issue?	No

Analysis Population Description
Intention-to-treat analysis set

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Measured Values

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Number of Participants Analyzed	100	100	100
Ventilator-free Days (VFDs) Over 28 Days [units: Days] Median (Full Range)	21.0 (0 to 28)	17.5 (0 to 28)	19.0 (0 to 28)

2. Secondary Outcome Measure:

Measure Title	7-day Mortality

Measure Description	Number of patients who died over 7 days
Time Frame	Over 7 days following first dose
Safety Issue?	Yes

Analysis Population Description
Intention-to-treat analysis set

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Measured Values

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Number of Participants Analyzed	100	100	100
7-day Mortality [units: Participants]	9	9	10

3. Secondary Outcome Measure:

Measure Title	28-day Mortality
Measure Description	Number of patients who died over 28 days
Time Frame	Over 28 days following first dose
Safety Issue?	Yes

Analysis Population Description
Intention-to-treat analysis set

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV

	Description
Placebo	Saline

Measured Values

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Number of Participants Analyzed	100	100	100
28-day Mortality [units: Participants]	15	27	20

4. Secondary Outcome Measure:

Measure Title	Safety and Tolerability
Measure Description	Number of patients with treatment-emergent adverse events
Time Frame	All study visits (over 90 days following first dose)
Safety Issue?	Yes

Analysis Population Description
Safety Analysis Set

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Measured Values

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
Number of Participants Analyzed	100	97	99
Safety and Tolerability [units: Participants]	86	87	92

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	One patient received incorrect dose of AZD9773, which explains the difference between the 2 AZD9773 dose groups for the patients in the following tables for adverse events.

Reporting Groups

	Description
AZD9773 250/50 Units/kg	AZD9773 250/50 units/kg IV
AZD9773 500/100 Units/kg	AZD9773 500/100 units/kg IV
Placebo	Saline

Serious Adverse Events

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	28/100 (28%)	27/97 (27.84%)	31/99 (31.31%)
Cardiac disorders			
Acute Myocardial Infarction [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Arrhythmia [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Atrial Fibrillation [A] †	0/100 (0%)	0/97 (0%)	2/99 (2.02%)
Cardiac Arrest [A] †	0/100 (0%)	1/97 (1.03%)	1/99 (1.01%)
Cardiac Failure Acute [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Cardiogenic Shock [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Sick Sinus Syndrome [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Endocrine disorders			
Inappropriate Antidiuretic Hormone Secretion [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Gastrointestinal disorders			
Abdominal Pain [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Abdominal Wall Abscess [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Diarrhoea [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Gastrointestinal Fistula [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Gastrointestinal Haemorrhage [A] †	1/100 (1%)	2/97 (2.06%)	1/99 (1.01%)
Gastrointestinal Necrosis [A] †	1/100 (1%)	1/97 (1.03%)	0/99 (0%)
Intestinal Infarction [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Intestinal Ischaemia [A] †	0/100 (0%)	1/97 (1.03%)	2/99 (2.02%)
Intestinal Perforation [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Pancreatic Fistula [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Vomiting [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
General disorders			
Multi-Organ Failure [A] †	0/100 (0%)	3/97 (3.09%)	3/99 (3.03%)
Pyrexia [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Hepatobiliary disorders			
Biliary Tract Disorder [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Cholecystitis [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Cytolytic Hepatitis [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Hepatic Failure [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Hepatic Function Abnormal [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Hepatic Lesion [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Immune system disorders			
Drug Hypersensitivity [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Infections and infestations			

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Aspergillosis [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Device Related Sepsis [A] †	1/100 (1%)	0/97 (0%)	1/99 (1.01%)
Empyema [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Encephalitis Herpes [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Endocarditis [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Fungal Oesophagitis [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Infection [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Infectious Peritonitis [A] †	0/100 (0%)	1/97 (1.03%)	1/99 (1.01%)
Meningitis Staphylococcal [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Pneumonia [A] †	0/100 (0%)	2/97 (2.06%)	5/99 (5.05%)
Sepsis [A] †	2/100 (2%)	1/97 (1.03%)	1/99 (1.01%)
Septic Shock [A] †	2/100 (2%)	2/97 (2.06%)	1/99 (1.01%)
Systemic Candida [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Tracheobronchitis [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Injury, poisoning and procedural complications			
Splenic Rupture [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Subdural Haematoma [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bile Duct Cancer [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Colon Cancer [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Oesophageal Carcinoma [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Rectal Cancer [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Nervous system disorders			
Autonomic Nervous System Imbalance [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Cerebral Infarction [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Convulsion [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Critical Illness Polyneuropathy [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Guillain-Barre Syndrome [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Hepatic Encephalopathy [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Ischaemic Stroke [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Polyneuropathy [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Psychiatric disorders			
Abnormal Behaviour [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Renal and urinary disorders			
Renal Failure [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Renal Failure Acute [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Respiratory, thoracic and mediastinal disorders			
Acute Pulmonary Oedema [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Acute Respiratory Distress Syndrome [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Haemoptysis [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Hypoxia [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Pleural Effusion [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Pneumonia Aspiration [A] †	0/100 (0%)	0/97 (0%)	3/99 (3.03%)
Pneumothorax [A] †	0/100 (0%)	2/97 (2.06%)	1/99 (1.01%)
Pulmonary Embolism [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Respiratory Distress [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Respiratory Failure [A] †	4/100 (4%)	0/97 (0%)	1/99 (1.01%)
Respiratory Gas Exchange Disorder [A] †	0/100 (0%)	1/97 (1.03%)	0/99 (0%)
Skin and subcutaneous tissue disorders			
Rash Vesicular [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Vascular disorders			
Air Embolism [A] †	1/100 (1%)	0/97 (0%)	0/99 (0%)
Extremity Necrosis [A] †	0/100 (0%)	1/97 (1.03%)	1/99 (1.01%)
Ischaemia [A] †	0/100 (0%)	0/97 (0%)	1/99 (1.01%)
Shock [A] †	2/100 (2%)	1/97 (1.03%)	0/99 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 14.1

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	74/100 (74%)	71/97 (73.2%)	68/99 (68.69%)
Blood and lymphatic system disorders			
Anaemia [A] †	20/100 (20%)	18/97 (18.56%)	22/99 (22.22%)
Thrombocytopenia [A] †	5/100 (5%)	4/97 (4.12%)	4/99 (4.04%)
Cardiac disorders			
Atrial Fibrillation [A] †	11/100 (11%)	14/97 (14.43%)	8/99 (8.08%)
Gastrointestinal disorders			
Constipation [A] †	7/100 (7%)	11/97 (11.34%)	9/99 (9.09%)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Diarrhoea [A] †	12/100 (12%)	9/97 (9.28%)	14/99 (14.14%)
Nausea [B] †	5/100 (5%)	2/97 (2.06%)	7/99 (7.07%)
Vomiting [A] †	5/100 (5%)	2/97 (2.06%)	5/99 (5.05%)
General disorders			
Generalised Oedema [A] †	6/100 (6%)	2/97 (2.06%)	4/99 (4.04%)
Oedema [A] †	4/100 (4%)	2/97 (2.06%)	5/99 (5.05%)
Oedema Peripheral [A] †	3/100 (3%)	3/97 (3.09%)	5/99 (5.05%)
Pyrexia [A] †	6/100 (6%)	5/97 (5.15%)	5/99 (5.05%)
Infections and infestations			
Pneumonia [A] †	5/100 (5%)	4/97 (4.12%)	7/99 (7.07%)
Urinary Tract Infection [A] †	2/100 (2%)	6/97 (6.19%)	7/99 (7.07%)
Metabolism and nutrition disorders			
Fluid Overload [A] †	3/100 (3%)	5/97 (5.15%)	3/99 (3.03%)
Hyperglycaemia [A] †	2/100 (2%)	1/97 (1.03%)	5/99 (5.05%)
Hyperkalaemia [A] †	6/100 (6%)	3/97 (3.09%)	5/99 (5.05%)
Hypernatraemia [A] †	6/100 (6%)	3/97 (3.09%)	4/99 (4.04%)
Hypoalbuminaemia [A] †	4/100 (4%)	1/97 (1.03%)	5/99 (5.05%)
Hypoglycaemia [A] †	5/100 (5%)	5/97 (5.15%)	2/99 (2.02%)
Hypokalaemia [A] †	10/100 (10%)	9/97 (9.28%)	5/99 (5.05%)
Hypophosphataemia [A] †	5/100 (5%)	2/97 (2.06%)	6/99 (6.06%)
Psychiatric disorders			
Agitation [A] †	6/100 (6%)	7/97 (7.22%)	8/99 (8.08%)
Anxiety [A] †	6/100 (6%)	1/97 (1.03%)	7/99 (7.07%)

	AZD9773 250/50 Units/kg	AZD9773 500/100 Units/kg	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Confusional State [A] †	7/100 (7%)	4/97 (4.12%)	5/99 (5.05%)
Insomnia [A] †	5/100 (5%)	3/97 (3.09%)	11/99 (11.11%)
Respiratory, thoracic and mediastinal disorders			
Pleural Effusion [A] †	6/100 (6%)	7/97 (7.22%)	4/99 (4.04%)
Skin and subcutaneous tissue disorders			
Decubitus Ulcer [A] †	4/100 (4%)	5/97 (5.15%)	6/99 (6.06%)
Rash [A] †	5/100 (5%)	3/97 (3.09%)	4/99 (4.04%)
Vascular disorders			
Hypertension [A] †	5/100 (5%)	5/97 (5.15%)	7/99 (7.07%)
Hypotension [A] †	4/100 (4%)	5/97 (5.15%)	5/99 (5.05%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 14.1
B Term from vocabulary, MedDRA 14

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.

Results Point of Contact:

Name/Official Title: Justin Lindemann
Organization: AstraZeneca
Phone:

Email: ClinicalTrialTransparency@astrazeneca.com